vs
Side-by-side financial comparison of FEMASYS INC (FEMY) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
FEMASYS INC is the larger business by last-quarter revenue ($813.4K vs $421.0K, roughly 1.9× SenesTech, Inc.). SenesTech, Inc. runs the higher net margin — -428.5% vs -485.7%, a 57.2% gap on every dollar of revenue. On growth, FEMASYS INC posted the faster year-over-year revenue change (39.9% vs -16.0%). SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-4.3M). Over the past eight quarters, FEMASYS INC's revenue compounded faster (73.2% CAGR vs 0.7%).
Femasys Inc. is a medical technology firm specializing in developing and commercializing minimally invasive diagnostic and therapeutic devices for women's health. Its core products address unmet clinical needs in fertility care, gynecology and obstetrics, serving healthcare providers and patients mainly across North American and European markets.
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
FEMY vs SNES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $813.4K | $421.0K |
| Net Profit | $-4.0M | $-1.8M |
| Gross Margin | 62.7% | 55.3% |
| Operating Margin | -568.3% | -446.8% |
| Net Margin | -485.7% | -428.5% |
| Revenue YoY | 39.9% | -16.0% |
| Net Profit YoY | 22.9% | -43.7% |
| EPS (diluted) | $0.02 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $813.4K | $421.0K | ||
| Q3 25 | $729.4K | $690.0K | ||
| Q2 25 | $409.3K | $625.0K | ||
| Q1 25 | $341.3K | $485.0K | ||
| Q4 24 | $581.6K | $501.0K | ||
| Q3 24 | $554.9K | $482.0K | ||
| Q2 24 | $221.5K | $459.0K | ||
| Q1 24 | $271.1K | $415.0K |
| Q4 25 | $-4.0M | $-1.8M | ||
| Q3 25 | $-4.2M | $-1.3M | ||
| Q2 25 | $-4.6M | $-1.6M | ||
| Q1 25 | $-5.9M | $-1.7M | ||
| Q4 24 | $-5.1M | $-1.3M | ||
| Q3 24 | $-5.4M | $-1.5M | ||
| Q2 24 | $-4.7M | $-1.6M | ||
| Q1 24 | $-3.6M | $-1.8M |
| Q4 25 | 62.7% | 55.3% | ||
| Q3 25 | 59.7% | 62.8% | ||
| Q2 25 | 61.4% | 65.4% | ||
| Q1 25 | 65.6% | 64.5% | ||
| Q4 24 | 66.9% | 60.9% | ||
| Q3 24 | 65.6% | 65.4% | ||
| Q2 24 | 67.0% | 54.2% | ||
| Q1 24 | 67.3% | 32.5% |
| Q4 25 | -568.3% | -446.8% | ||
| Q3 25 | -500.9% | -195.2% | ||
| Q2 25 | -941.1% | -258.2% | ||
| Q1 25 | -1600.1% | -342.9% | ||
| Q4 24 | -812.0% | -250.9% | ||
| Q3 24 | -922.4% | -321.0% | ||
| Q2 24 | -2023.7% | -349.0% | ||
| Q1 24 | -1277.1% | -444.1% |
| Q4 25 | -485.7% | -428.5% | ||
| Q3 25 | -575.1% | -188.1% | ||
| Q2 25 | -1120.5% | -258.6% | ||
| Q1 25 | -1727.9% | -343.3% | ||
| Q4 24 | -881.0% | -250.5% | ||
| Q3 24 | -974.7% | -313.9% | ||
| Q2 24 | -2115.1% | -345.1% | ||
| Q1 24 | -1327.5% | -441.4% |
| Q4 25 | $0.02 | $0.48 | ||
| Q3 25 | $-0.10 | $-0.28 | ||
| Q2 25 | $-0.16 | $-0.87 | ||
| Q1 25 | $-0.23 | $-1.28 | ||
| Q4 24 | $-0.23 | $-0.15 | ||
| Q3 24 | $-0.24 | $-2.07 | ||
| Q2 24 | $-0.21 | $-3.08 | ||
| Q1 24 | $-0.17 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.3M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | $9.6M |
| Total Assets | $20.7M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.3M | $8.6M | ||
| Q3 25 | $4.6M | $10.2M | ||
| Q2 25 | $3.2M | $6.1M | ||
| Q1 25 | $3.8M | $1.7M | ||
| Q4 24 | $3.5M | $1.3M | ||
| Q3 24 | $7.6M | $2.5M | ||
| Q2 24 | $13.5M | $2.0M | ||
| Q1 24 | $17.8M | $3.6M |
| Q4 25 | $5.9M | $9.6M | ||
| Q3 25 | $4.6M | $11.3M | ||
| Q2 25 | $1.5M | $7.0M | ||
| Q1 25 | $2.0M | $2.9M | ||
| Q4 24 | $2.3M | $2.5M | ||
| Q3 24 | $6.0M | $3.7M | ||
| Q2 24 | $11.3M | $3.1M | ||
| Q1 24 | $15.6M | $4.6M |
| Q4 25 | $20.7M | $12.8M | ||
| Q3 25 | $16.3M | $14.6M | ||
| Q2 25 | $13.8M | $10.4M | ||
| Q1 25 | $13.3M | $3.6M | ||
| Q4 24 | $12.4M | $3.3M | ||
| Q3 24 | $15.6M | $4.4M | ||
| Q2 24 | $20.3M | $4.0M | ||
| Q1 24 | $24.4M | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-1.7M |
| Free Cash FlowOCF − Capex | $-4.3M | $-1.7M |
| FCF MarginFCF / Revenue | -531.7% | -398.3% |
| Capex IntensityCapex / Revenue | 17.2% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-19.2M | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.2M | $-1.7M | ||
| Q3 25 | $-5.4M | $-1.4M | ||
| Q2 25 | $-4.4M | $-1.1M | ||
| Q1 25 | $-4.8M | $-1.6M | ||
| Q4 24 | $-5.1M | $-1.2M | ||
| Q3 24 | $-5.5M | $-1.4M | ||
| Q2 24 | $-4.3M | $-1.6M | ||
| Q1 24 | $-4.6M | $-1.8M |
| Q4 25 | $-4.3M | $-1.7M | ||
| Q3 25 | $-5.6M | $-1.4M | ||
| Q2 25 | $-4.4M | $-1.2M | ||
| Q1 25 | $-4.9M | $-1.6M | ||
| Q4 24 | $-5.2M | $-1.2M | ||
| Q3 24 | $-5.9M | $-1.4M | ||
| Q2 24 | $-4.5M | $-1.6M | ||
| Q1 24 | $-4.6M | $-1.8M |
| Q4 25 | -531.7% | -398.3% | ||
| Q3 25 | -765.3% | -205.9% | ||
| Q2 25 | -1086.6% | -191.5% | ||
| Q1 25 | -1424.7% | -328.5% | ||
| Q4 24 | -890.9% | -246.1% | ||
| Q3 24 | -1060.1% | -296.1% | ||
| Q2 24 | -2035.8% | -354.2% | ||
| Q1 24 | -1708.6% | -441.2% |
| Q4 25 | 17.2% | 3.1% | ||
| Q3 25 | 26.6% | 6.1% | ||
| Q2 25 | 23.0% | 7.5% | ||
| Q1 25 | 28.3% | 7.4% | ||
| Q4 24 | 18.4% | 3.0% | ||
| Q3 24 | 73.5% | 5.8% | ||
| Q2 24 | 82.4% | 8.5% | ||
| Q1 24 | 23.8% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
